

CARDIOLOGY

PAPER-III

Time: 3 hours
Max. Marks:100

CARD/D/20/05/III

Important Instructions:

- *You are provided with 5 answer sheet booklets. Each individual answer sheet booklet consists of 10 pages excluding the covering jackets.*
- *Answers to all the questions must be attempted within these 5 answer sheet booklets which must be later tagged together at the end of the exam.*
- *No additional supplementary answer sheet booklet will be provided.*
- *Attempt all questions in order.*
- *Each question carries 10 marks.*
- *Read the question carefully and answer to the point neatly and legibly.*
- *Do not leave any blank pages between two answers.*
- *Indicate the question number correctly for the answer in the margin space.*
- *Answer all the parts of a single question together.*
- *Start the answer to a question on a fresh page or leave adequate space between two answers.*
- *Draw table/diagrams/flowcharts wherever appropriate.*

Write short notes on:

1. Coronary debulking strategies and devices: current status 10
2. a) LoDoCo2 study. 5+5
b) The TICO Trial.
3. a) 3D Echocardiography: Concept and clinical applications. 5+5
b) Assessment of ASD size during percutaneous ASD closure.
4. a) Interventions for smoking cessation. 5+5
b) Evidence based interventions to raise HDL cholesterol.
5. Enumerate various palliative surgical procedures in congenital heart. 10
disease treatment. Describe in brief at least 4 such procedures.
6. a) COVID-19 and cardiovascular disease: describe briefly various 5+5
manifestations and treatment.
b) SGLT2 inhibitors in heart failure: current status.
7. Distal myocardial preservation/protection during percutaneous coronary 10
intervention: when and how.
8. a) Shifting burden and epidemiologic transitions: Five typical stages of 5+5
epidemiological transitions in CVD mortality and types.
b) Coronary artery disease epidemiology in India: current trends.
9. a) Remote monitoring devices for arrhythmia: types, indications and 5+5
Limitations.
b) Physiologic pacing strategies: Indications and technique.
10. a) Novel pharmacotherapies for pulmonary arterial hypertension in 2021. 5+5
b) ECMO: indications and limitations.
